VACCINES AGAINST DENGUE VIRUS

Team Members

Andzoa N. Jamus

We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for dengue virus vaccines.  We identify antigens of interest that are important for dengue virus infection and pathogenesis, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block dengue virus infection or key functions of the antigens.

Funding:

NIH/NIAID R21 AI148836 to Kathryn M. Frietze

UNM School of Medicine RAC grant to Kathryn M. Frietze

NIH/NIAID T32 Pre-Doctoral Fellowship to Andzoa N. Jamus

mosquito_edited.jpg